Novartis (NOVN.SW) Aandeel Koers
Novartis Koers
De omzet is de afgelopen 19 jaar met 2,6% per jaar gegroeid tot 46,49 Miljard USD. De winst per aandeel is de afgelopen 19 jaar met 4,9% per jaar gegroeid. De nettowinstmarge van Novartis ligt op 25,6% en is ten opzichte van 54,6% enkele jaren eerder gedaald. Novartis biedt momenteel een dividendrendement van circa 2,43%. De uitkeringsratio ligt rond 68% van de winst. Het dividend is de afgelopen 19 jaar met 7,1% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 142,22 USD — dat impliceert 1,2% onder de huidige koers. Van de 34 analisten geven 17 het aandeel een koopadvies — per saldo een Kopen-consensus.
Novartis aandeelkoers
Novartis bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Novartis
The business model of Novartis AG focuses on the development, manufacturing, and commercialization of innovative healthcare solutions. As one of the leading pharmaceutical companies globally, Novartis AG operates in three main segments: Pharmaceuticals, which includes patented prescription medicines; Alcon, which deals with eye care products; and Sandoz, responsible for generic pharmaceuticals and biosimilars. Novartis AG strives to improve patient outcomes by investing heavily in research and development, collaborating with healthcare professionals, and implementing cutting-edge technologies. By combining scientific expertise with a patient-centric approach, Novartis AG aims to address unmet medical needs and contribute to the advancement of healthcare worldwide.
Novartis AG is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Novartis AG in the market include Pfizer, Johnson & Johnson, Roche Holding AG, and Merck & Co. These companies are major players in the pharmaceutical industry and compete with Novartis in various therapeutic areas. While Novartis is renowned for its innovative drugs and extensive product portfolio spanning pharmaceuticals, generics, and biologics, it faces strong competition from these prominent industry leaders. Each competitor brings its own strengths and focuses on different therapeutic areas, leading to intense competition in the global pharmaceutical market.
Novartis AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. Founded in 1996, Novartis was formed through the merger of Ciba-Geigy and Sandoz, two pharmaceutical giants with long-standing histories. With a rich heritage tracing back to over 250 years, Novartis has established itself as a leading player in the global healthcare industry. The company specializes in the research, development, and manufacturing of a wide range of pharmaceuticals, including prescription drugs, generics, vaccines, and consumer health products. Novartis operates in over 150 countries, employing thousands of dedicated professionals worldwide, and remains committed to delivering innovative and high-quality healthcare solutions to improve and extend people's lives.
Novartis AG, a renowned pharmaceutical company, has achieved significant milestones throughout its history. It has successfully developed innovative drugs and made notable contributions to medical advancements. Notably, Novartis AG introduced groundbreaking treatments like Gleevec, a targeted therapy for chronic myeloid leukemia. The company also played a pivotal role in the development of CAR-T cell therapy, a revolutionary treatment for certain types of cancer. Novartis AG continues to focus on research and development, striving to improve patient outcomes and address unmet medical needs. With its commitment to innovation and impactful discoveries, Novartis AG maintains its position as a leading player in the pharmaceutical industry.
Novartis AG is primarily present in various countries and regions across the globe. With its headquarters in Switzerland, the company has a strong presence in Europe, including countries like Germany, France, and the United Kingdom. It also operates significantly in North America, particularly the United States, where it has a robust market presence. Novartis AG has established operations in Asia, specifically in Japan, China, and India, tapping into the rapidly growing pharmaceutical markets in these regions. Furthermore, the company has a significant foothold in Latin America, including countries like Brazil and Mexico, as well as a growing presence in Africa and the Middle East.
Novartis AG, a leading pharmaceutical company, upholds a strong set of values and a clear corporate philosophy. The company is committed to innovation, aiming to improve global health by developing innovative medicines and solutions. Novartis AG places great emphasis on ethics, integrity, and sustainability, ensuring that its operations adhere to the highest standards of ethical behavior. The company focuses on patient-centricity, prioritizing the well-being and needs of patients in the development and delivery of its products. Novartis AG also promotes diversity and inclusion, fostering a culture that embraces different perspectives and experiences. Through its dedication to these principles, Novartis AG strives to make a positive impact on society and enhance healthcare worldwide.
Analisten hanteren momenteel een gemiddeld koersdoel van 139,81 USD voor het aandeel Novartis (mediaan: 142,22 USD), oftewel -2,9 % ten opzichte van de laatste koers. De consensus is gebaseerd op 34 analistenratings.
34 analisten beoordelen het aandeel Novartis momenteel: 17 adviseren kopen, 13 houden en 4 verkopen. Voor 2026 verwachten analisten dat Novartis een omzet van 57,16 Miljard USD en winst per aandeel van 8,92 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Novartis op 128,56 EUR (143,98 USD).
Het aandeel Novartis (NOVN.SW) is genoteerd aan 7 beurzen, waaronder: London (0QLR.L), SIX (Zürich) (NOVN.SW), Frankfurt (NOT.F), München (NOT.MU), Düsseldorf (NOT.DU), Hamburg (NOT.HM).
Novartis AG is an international pharmaceutical and biotechnology company based in Basel, Switzerland. The company has been listed on the New York Stock Exchange (NYSE) since 1996 and operates in four main segments: Pharma, Alcon, Sandoz, and Consumer Health. In the Pharma segment, Novartis offers a wide range of prescription drugs focused on various therapy areas such as oncology, neurology, cardiology, and immunology. In 2020, the Pharma segment accounted for approximately 64% of the company's total revenue. One of Novartis's most well-known drugs is the cancer medication Glivec, which generated sales of nearly $3.3 billion in 2020. Novartis's Alcon segment is a leading provider of ophthalmology products and services. The segment offers a wide range of products, from contact lenses to surgical instruments and devices. In 2020, Alcon contributed approximately 18% to the company's total revenue. Some of Alcon's well-known products include the contact lens brands Air Optix and Dailies, as well as the Verion surgical system. The Sandoz segment of Novartis specializes in the development, manufacturing, and marketing of generics and biosimilars. Biosimilars are copies of biological drugs that are already on the market. The Sandoz segment offers a wide range of medications, from painkillers to cancer drugs. In 2020, Sandoz accounted for approximately 11% of the company's total revenue. Novartis's Consumer Health segment offers a wide range of over-the-counter (OTC) health products focused on dermatology, ophthalmology, and orthopedics. Consumer Health products are available in more than 140 countries. Some of the well-known brands of Consumer Health include Voltaren, Excedrin, and Nicotinell. In 2020, Consumer Health contributed approximately 7% to the company's total revenue. Novartis heavily invests in research and development (R&D) to develop new products and therapies. In 2020, Novartis spent nearly $10 billion on R&D, which represents approximately 18% of its revenue. The company collaborates closely with external partners to develop and bring innovative therapies to the market. To achieve growth, Novartis also relies on targeted acquisitions. In 2020, the company acquired US biotech company The Medicines Company for $9.7 billion to strengthen its activities in the cardiovascular disease area. Overall, Novartis pursues a diversified business model based on a strong presence in various therapy areas and geographical regions. The company focuses on investments in R&D and targeted acquisitions to drive its growth.
De verwachte omzet van Novartis bedraagt 57,16 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Novartis bedraagt 17,21 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Novartis bedraagt momenteel 16,14. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Novartis-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Novartis bedraagt momenteel 4,86. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Novartis-aandeel.
De Eulerpool Kwaliteitsscore voor Novartis is 7/10.
De ISIN van Novartis is CH0012005267. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Novartis is 904278. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Novartis is NOVN.SW. Onder dit beurstickersymbool wordt het Novartis-aandeel op de beurs verhandeld.
Novartis aandeel
Novartis Peer Group
Novartis Ticker
Novartis FIGI
Alle fundamentals en diepgaande analyse van Novartis
Onze aandelenanalyse van het Novartis-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Novartis. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: